HN2008000974A - Derivados de bencimidazol - Google Patents

Derivados de bencimidazol

Info

Publication number
HN2008000974A
HN2008000974A HN2008000974A HN2008000974A HN2008000974A HN 2008000974 A HN2008000974 A HN 2008000974A HN 2008000974 A HN2008000974 A HN 2008000974A HN 2008000974 A HN2008000974 A HN 2008000974A HN 2008000974 A HN2008000974 A HN 2008000974A
Authority
HN
Honduras
Prior art keywords
bencimidazol
derivatives
bencimidazol derivatives
composite
document
Prior art date
Application number
HN2008000974A
Other languages
English (en)
Inventor
Scott Jones Christopher
La Greca Susdan
Li Qifang
John Munchof Michael
Alan Reiter Lawrence
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HN2008000974A publication Critical patent/HN2008000974A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

ESTA INVENCION SE REFIERE A UN COMPUESTO DE FORMULA I O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO EN LA QUE R1,R2,,R3A, R3B,R4,R5,X, M Y N SON COMO SE DEFINE EN EL PRESENTE DOCUMENTO
HN2008000974A 2007-06-29 2008-06-25 Derivados de bencimidazol HN2008000974A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02

Publications (1)

Publication Number Publication Date
HN2008000974A true HN2008000974A (es) 2011-01-24

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2008000974A HN2008000974A (es) 2007-06-29 2008-06-25 Derivados de bencimidazol

Country Status (46)

Country Link
US (2) US8148401B2 (es)
EP (1) EP2170860B9 (es)
JP (2) JP4567099B2 (es)
KR (1) KR101143246B1 (es)
CN (1) CN101687841B (es)
AP (1) AP2377A (es)
AR (1) AR067346A1 (es)
AU (1) AU2008272641B2 (es)
BR (1) BRPI0813412B8 (es)
CA (1) CA2690953C (es)
CL (1) CL2008001922A1 (es)
CO (1) CO6160232A2 (es)
CR (1) CR11150A (es)
CU (1) CU23847B1 (es)
CY (2) CY1118650T1 (es)
DK (1) DK2170860T5 (es)
DO (1) DOP2009000278A (es)
EA (1) EA016888B1 (es)
EC (1) ECSP099803A (es)
ES (1) ES2609258T3 (es)
FR (1) FR20C1038I2 (es)
GE (1) GEP20125702B (es)
GT (1) GT200900328A (es)
HK (1) HK1139658A1 (es)
HN (1) HN2008000974A (es)
HR (1) HRP20161562T2 (es)
HU (2) HUE030052T4 (es)
IL (1) IL202420A (es)
LT (2) LT2170860T (es)
MA (1) MA31466B1 (es)
ME (1) ME00962B (es)
MY (1) MY148636A (es)
NI (1) NI200900219A (es)
NL (1) NL301057I2 (es)
NO (1) NO2020027I1 (es)
NZ (1) NZ581889A (es)
PA (1) PA8785401A1 (es)
PE (2) PE20090772A1 (es)
PL (1) PL2170860T3 (es)
PT (1) PT2170860T (es)
RS (1) RS55395B9 (es)
SI (1) SI2170860T1 (es)
TN (1) TN2009000544A1 (es)
TW (1) TWI371451B (es)
UY (1) UY31164A1 (es)
WO (1) WO2009004427A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148636A (en) * 2007-06-29 2013-05-15 Pfizer Benzimidazole derivatives
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
WO2010142426A1 (en) * 2009-06-11 2010-12-16 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
EP2471790B1 (en) 2009-08-26 2015-03-18 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
ES2543151T3 (es) 2010-10-20 2015-08-17 Pfizer Inc Derivados de 2-piridina como moduladores del receptor Smoothened
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Ｎｔｔドコモ ホーム基地局及びハンドオーバ方法
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
PT2680694T (pt) 2011-02-28 2019-03-14 Biomarin Pharm Inc Inibidores de histona deacetilase
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9051305B2 (en) 2011-03-08 2015-06-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
ES2612934T3 (es) * 2011-09-26 2017-05-19 Merck Patent Gmbh Compuestos de piperidin bencilo como antagonista del receptor del ácido lisofosfatídico (LPA)
US20150133450A1 (en) 2012-06-20 2015-05-14 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
JP6503338B2 (ja) 2013-03-15 2019-04-17 バイオマリン ファーマシューティカル インコーポレイテッド Ｈｄａｃ阻害剤
US10435364B2 (en) 2013-04-17 2019-10-08 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
WO2015017788A1 (en) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
US10640803B2 (en) 2013-10-30 2020-05-05 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
RU2717564C2 (ru) * 2015-04-24 2020-03-24 Пфайзер Инк. Кристаллические формы 1-((2r,4r)-2-(1h-бензо[d]имидазол-2-ил)-1-метилпиперидин 4-ил)-3-(4-цианофенил)мочевины малеата
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2020164722A (ja) * 2019-03-29 2020-10-08 デクセリアルズ株式会社 接着剤組成物
EP4327881A3 (en) 2020-01-28 2024-04-17 Assia Chemical Industries Ltd. Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
EP4126237B1 (en) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
US20230301950A1 (en) 2020-06-26 2023-09-28 Raqualia Pharma Inc. Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE443518T1 (de) * 2001-07-27 2009-10-15 Curis Inc Vermittler von igel-signalpfaden, zusammensetzungen und relevante verwendungszwecke
IL162851A0 (en) 2001-12-04 2005-11-20 Actelion Pharmaceuticals Ltd 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
PL377215A1 (pl) 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
WO2005042495A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
JP2007521325A (ja) 2003-10-28 2007-08-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド イオンチャネルのモジュレーターとして有用なベンズイミダゾール
AU2005301962B2 (en) 2004-11-03 2011-10-20 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE102005012875B4 (de) * 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2008064830A1 (en) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses
US20100029615A1 (en) 2006-12-15 2010-02-04 Michael John Munchhof Benzimidazole derivatives
MY148636A (en) 2007-06-29 2013-05-15 Pfizer Benzimidazole derivatives
WO2009154739A2 (en) 2008-06-17 2009-12-23 Duke University Smoothened receptor modulators
WO2010027746A2 (en) 2008-08-25 2010-03-11 Irm Llc Hedgehog pathway modulators

Also Published As

Publication number Publication date
AU2008272641B2 (en) 2013-08-29
JP2010280693A (ja) 2010-12-16
AU2008272641A1 (en) 2009-01-08
MA31466B1 (fr) 2010-06-01
EA200971104A1 (ru) 2010-06-30
KR20100028120A (ko) 2010-03-11
US8148401B2 (en) 2012-04-03
ES2609258T3 (es) 2017-04-19
DK2170860T3 (en) 2017-01-09
EP2170860B9 (en) 2017-02-22
CU23847B1 (es) 2012-10-15
UY31164A1 (es) 2009-01-30
TW200911792A (en) 2009-03-16
CA2690953A1 (en) 2009-01-08
EP2170860A2 (en) 2010-04-07
WO2009004427A3 (en) 2009-06-04
PT2170860T (pt) 2017-01-04
WO2009004427A2 (en) 2009-01-08
FR20C1038I1 (es) 2020-10-02
LTPA2020528I1 (lt) 2020-09-25
RS55395B9 (sr) 2020-01-31
KR101143246B1 (ko) 2012-05-18
IL202420A0 (en) 2010-06-30
BRPI0813412A2 (pt) 2014-12-30
DOP2009000278A (es) 2009-12-31
NL301057I1 (nl) 2020-07-22
NL301057I2 (nl) 2020-09-10
US8431597B2 (en) 2013-04-30
MY148636A (en) 2013-05-15
CL2008001922A1 (es) 2009-01-02
HUS2000031I1 (hu) 2020-09-28
ME00962B (me) 2012-06-20
CY2020028I1 (el) 2020-11-25
LT2170860T (lt) 2017-01-10
PL2170860T3 (pl) 2017-05-31
EA016888B1 (ru) 2012-08-30
HK1139658A1 (en) 2010-09-24
NZ581889A (en) 2011-05-27
JP4567099B2 (ja) 2010-10-20
US20090005416A1 (en) 2009-01-01
PE20121010A1 (es) 2012-08-06
JP2010531869A (ja) 2010-09-30
IL202420A (en) 2014-05-28
CU20090225A7 (es) 2012-02-15
TWI371451B (en) 2012-09-01
BRPI0813412B8 (pt) 2021-05-25
NO2020027I1 (no) 2020-08-11
CO6160232A2 (es) 2010-05-20
BRPI0813412B1 (pt) 2020-01-21
TN2009000544A1 (fr) 2011-03-31
DK2170860T5 (en) 2017-03-20
CY1118650T1 (el) 2017-07-12
HUE030052T2 (hu) 2017-04-28
EP2170860B1 (en) 2016-11-02
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
LTC2170860I2 (lt) 2022-03-10
PA8785401A1 (es) 2009-01-23
HUE030052T4 (en) 2017-06-28
CR11150A (es) 2010-02-08
AP2009005089A0 (en) 2009-12-31
SI2170860T1 (sl) 2017-01-31
GEP20125702B (en) 2012-12-10
GT200900328A (es) 2011-08-29
CN101687841B (zh) 2013-07-10
HRP20161562T1 (hr) 2016-12-30
CN101687841A (zh) 2010-03-31
RS55395B1 (sr) 2017-04-28
FR20C1038I2 (fr) 2021-08-13
AR067346A1 (es) 2009-10-07
ECSP099803A (es) 2010-01-29
AP2377A (en) 2012-03-07
CA2690953C (en) 2012-10-02
HRP20161562T2 (hr) 2017-04-21
CY2020028I2 (el) 2020-11-25
US20120157495A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
HN2008000974A (es) Derivados de bencimidazol
SMT201500036B (it) Derivati di cromenone con attivita' antitumorale
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
BRPI1006801A2 (pt) revestimento exterior reutilizável para artigos absorventes do tipo para vestir
ECSP088632A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina
HN2007015177A (es) Derivados de triazolopirazina
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
BRPI0817562A2 (pt) derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
CR20110141S (es) Montaje de stent quirurgico
CR9280S (es) Botella
HN2006037713A (es) Compuestos utiles en terapia
BRPI1008899A2 (pt) derivados 3,3´-espiroindolinona como agentes anticâncer
IT1391030B1 (it) Veicolo del tipo a guida a cavalcioni avente un cilindro principale posteriore
HN2011003403A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
CR9344S (es) Regadera
DOP2009000264A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina
BRPI0821021A2 (pt) Compostos de amida como reforçadores de antivirais
CR20110701A (es) Derivados de pirazoles, su preparacion y su aplicacion terapeutica.
DK2406337T3 (da) Fastgørelsesorgan
DK2403509T3 (da) Aktiveret leukocytsammensætning
DE502007004713D1 (de) Karosserie-Anbauteil
SE0900379L (sv) Benstöd
CR9341S (es) Boquilla
ES1072281Y (es) Carroceria luminosa